Curis, Inc. (NASDAQ:CRIS) dropped 5.7% on Tuesday . The stock traded as low as $0.82 and last traded at $0.83. Approximately 3,282,700 shares changed hands during mid-day trading, an increase of 334% from the average daily volume of 755,714 shares. The stock had previously closed at $0.88.

CRIS has been the subject of several research analyst reports. Guggenheim initiated coverage on shares of Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. ValuEngine downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Finally, BidaskClub raised shares of Curis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Three research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. Curis currently has a consensus rating of “Hold” and an average price target of $6.50.

The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The business had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The firm’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) earnings per share. research analysts anticipate that Curis, Inc. will post -0.41 earnings per share for the current year.

In other news, CEO Ali Ph.D. Fattaey purchased 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the completion of the acquisition, the chief executive officer now owns 115,890 shares in the company, valued at $122,843.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.07% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in Curis by 62,201.8% during the third quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 2,377,975 shares during the last quarter. FNY Partners Fund LP boosted its holdings in Curis by 350.0% during the third quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 52,500 shares during the last quarter. First Eagle Investment Management LLC raised its position in Curis by 10.4% in the third quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock worth $39,498,000 after acquiring an additional 2,500,000 shares during the period. The Manufacturers Life Insurance Company raised its position in Curis by 8.8% in the second quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 8,102 shares during the period. Finally, State Street Corp raised its position in Curis by 10.4% in the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock worth $3,511,000 after acquiring an additional 175,424 shares during the period. Institutional investors and hedge funds own 55.22% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/12/07/curis-cris-stock-price-down-5-7.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.